
DD Stock Forecast & Price Target
DD Analyst Ratings
Bulls say
DuPont de Nemours's Healthcare & Water segment has demonstrated strong organic sales growth, driven by robust demand in medical packaging and biopharma, positioning the company favorably in these critical industries. The ongoing transition toward new product offerings, as evidenced by the vitality index improvements, is expected to enhance both pricing and volume in the coming years, further solidifying revenue streams. Additionally, anticipated growth in the Electronics & Industrial segment, fueled by advancements in 5G and IoT, underlines the company's potential for significant volume expansion and favorable valuation adjustments as it continues its portfolio transformation.
Bears say
DuPont de Nemours faces a negative outlook primarily due to anticipated delays in synergy realization post-merger, which hampers the company's ability to achieve operational efficiencies and cost savings. Additionally, ongoing weakness in the electronics and construction markets, compounded by a slower recovery in China, poses significant risks to revenue generation in key segments. These factors collectively threaten to undermine the profitability of DuPont’s core business areas, particularly in healthcare and water, which are expected to drive the bulk of its earnings.
This aggregate rating is based on analysts' research of DuPont de Nemours and is not a guaranteed prediction by Public.com or investment advice.
DD Analyst Forecast & Price Prediction
Start investing in DD
Order type
Buy in
Order amount
Est. shares
0 shares